RAC1 and prostate carcinoma: Thus, the observed unchanged activity of p38 and JNK following Rac1/Cdc42-inhibition by AZA1 suggests that these pathways play no major role in mediating AZA1-induced anti-proliferative effects in 22Rv1 prostate cancer cells.